Feed CNTB
CN

Connect Biopharma Holdings Limited CNTB · NASDAQ

$0.91 +0.01% (+$0.00)

Market cap
$57.1M
Enterprise value
$19.4M
P/E
-
Forward P/E
-
PEG
-
P/S
891.7x
P/FCF
-
EV/EBITDA
-
ROIC
-136.2%
Gross margin
100.0%
Net margin
-86,687.5%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
-0.22
Free float
26.2%

About the company

Connect Biopharma Holdings Limited (CNTB) is an international biotechnology company focused on researching, developing, and commercializing new drugs for the treatment of immunological disorders and cancer. With a primary focus on innovative therapeutic strategies and biologic drugs, Connect Biopharma aims to address unmet needs in the treatment of immune disorders and cancer. The company is known for its research capabilities and ability to discover new therapeutic pathways, as well as for its commitment to high standards of safety and efficacy. Shares of Connect Biopharma Holdings Limited (CNTB) could be suitable for investors looking to invest in the biotechnology sector with an emphasis on innovations in the treatment of immune disorders and cancer.

Sector

Healthcare

Industry

Biotechnology

CEO

Barry D. Quart

Employees

64

Headquarters

San Diego

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.